Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr
The company reported lifetime high EBIDTA of Rs. 250 crores
The company reported lifetime high EBIDTA of Rs. 250 crores
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
5C Network’s groundbreaking platform aims to bring together diagnostic facilities and healthcare aggregators on a single platform to deliver an unparalleled patient experience
navify Sample Tracking is part of the navify Diagnostics portfolio, a set of digital solutions enabling labs to drive end-to-end operational excellence across care settings.
Subscribe To Our Newsletter & Stay Updated